Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Benzer Materyaller

• Oncology Drugs Approved by the FDA in Early 2018
  Baskı/Yayın Bilgisi: (2018)
• FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma
  Yazar:: Bradford, Diana, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer
  Yazar:: Anscher, Mitchell S., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
  Yazar:: Raedler, Lisa A.
  Baskı/Yayın Bilgisi: (2015)
• Syntheses of FDA Approved HIV Protease Inhibitors
  Yazar:: Ghosh, Arun K., ve diğerleri
  Baskı/Yayın Bilgisi: (2001)